NVLN - Novelion Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.6800
-0.0200 (-2.86%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.7000
Open0.6000
Bid0.0000 x 800
Ask0.0000 x 1200
Day's Range0.5550 - 0.6800
52 Week Range0.5400 - 2.3500
Volume231,287
Avg. Volume113,313
Market Cap12.95M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 7, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.50
Trade prices are not sourced from all markets
  • GlobeNewswire

    Novelion Therapeutics Announces Nasdaq Delisting

    Novelion Therapeutics Inc. (NVLN) (“Novelion” or the “Company”), announced that on October 7, 2019 the Nasdaq Office of General Counsel notified the Company that the Nasdaq Hearing Panel (the “Panel”) has determined to affirm the Listing Qualifications Staff’s (“Staff”) decision to delist the Company’s shares from the Nasdaq Stock Market LLC (“Nasdaq”) and that trading of the Company’s common shares will be suspended effective at the open of business on October 9, 2019. The Company does not intend to seek review of or appeal the Panel’s determination.

  • GlobeNewswire

    Novelion Therapeutics Announces Filing of Definitive Proxy Statement in Connection with Proposed Liquidation and Other Matters

    Novelion Therapeutics Inc. (NVLN) (“Novelion” or the “Company”) today announced that it has filed its notice of meeting and definitive proxy statement with the applicable securities regulatory authorities in connection with the proposals to be voted on at the Company’s 2019 annual general meeting of shareholders (the “Annual Meeting”), including the proposed liquidation and dissolution of the Company (the “Liquidation Proposal”).  Novelion expects to commence mailing the definitive proxy statement and information circular (the “Proxy Materials”) to shareholders on or about October 4, 2019.

  • GlobeNewswire

    Novelion Therapeutics Announces Completion of Aegerion Transaction and Departure of Certain Directors and Officers

    Novelion Therapeutics Inc. (NVLN) (“Novelion” or the “Company”), announced that, further to its press release dated September 11, 2019, the acquisition by Amryt Pharma Plc (“Amryt”) of 100% of the outstanding equity interests of Novelion’s reorganized subsidiary, Aegerion Pharmaceuticals, Inc. (“Aegerion”) as contemplated in Aegerion’s First Amended Joint Chapter 11 Plan (the “Amryt Transaction”), has been completed. On September 24, 2019, Aegerion completed the Amryt Transaction (the “Closing”). The consideration for the Amryt Transaction has been satisfied through the issuance of ordinary Amryt shares (the “Ordinary Shares”), or American depository receipts representing Ordinary Shares, to stakeholders of Aegerion.

  • GlobeNewswire

    Novelion Therapeutics Announces US Court Confirmation of Aegerion Bankruptcy Case, Update on Nasdaq Delisting and Date of Annual General Meeting of Shareholders

    Novelion Therapeutics Inc. (NVLN) (“Novelion” or the “Company”), announced that, further to its press release dated August 30, 2019, the United States Bankruptcy Court for the Southern District of New York (the “Bankruptcy Court”) entered an order on September 10, 2019 confirming Aegerion’s First Amended Joint Chapter 11 Plan (the “Plan”), as modified to reflect certain resolutions agreed to among various parties. On May 20, 2019, as previously disclosed, Aegerion Pharmaceuticals, Inc. and Aegerion Pharmaceuticals Holdings, Inc. (together, “Aegerion”), each a subsidiary of the Company, filed voluntary petitions under chapter 11 of Title 11 of the United States Code in the Bankruptcy Court.

  • GlobeNewswire

    Novelion Therapeutics Provides Update Regarding Delisting from Nasdaq and Aegerion Bankruptcy Case

    Novelion Therapeutics Inc. (NVLN) (“Novelion” or the “Company”), announced that, further to its press release dated August 21, 2019, it has received a notice from the Nasdaq Hearings Panel (the “Panel”) granting a 15-calendar day stay, until September 12, 2019, of the delisting of the Company’s common stock from The Nasdaq Stock Market in response to the Company’s request for a hearing. Upon expiration of the stay period, the Company’s common stock will be suspended from trading unless the Panel extends the stay of delisting pending the hearing.

  • GlobeNewswire

    Novelion Therapeutics Announces Issuance of General Cease Trade Order in Canada and Notice of Delisting from Nasdaq

    VANCOUVER, British Columbia and CAMBRIDGE, Mass., Aug. 21, 2019 -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”) announced that, further to its press.

  • Benzinga

    The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 12) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 1) Down ...

  • GlobeNewswire

    Novelion Therapeutics Announces Anticipated Late Filing of Quarterly Report on Form 10-Q for the Quarter Ended June 30, 2019

    Novelion Therapeutics Inc. (NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases (“Novelion” or the “Company”), announced that it has determined that it will be unable to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, including the related management’s discussion and analysis and CEO and CFO certifications (collectively, the “Interim Disclosure”) by the filing deadline of August 14, 2019. In that regard, the Company has filed a Form 12b-25 (Notification of Late Filing) with the U.S. Securities and Exchange Commission (the “SEC”).  In addition, the Company will not be able to file the Interim Disclosure within the subsequent five-day extension permitted by the rules of the SEC (the “SEC Extension”).

  • GlobeNewswire

    Novelion Therapeutics Announces Dismissal of Whitefort Capital Petition

    VANCOUVER, British Columbia, July 16, 2019 -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for.

  • GlobeNewswire

    Novelion Therapeutics Receives Delisting Notifications

    Novelion Therapeutics Inc. (NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, announced that on July 3, 2019, the Company received a written notice from the Nasdaq Stock Market (“Nasdaq”) indicating that it is not in compliance with the requirement for continued listing on the Nasdaq Global Select Market to maintain a minimum Market Value of Publicly Held Shares (“MVPHS”) of $15,000,000, as set forth in Nasdaq Listing Rule 5450(b)(3)(C). Also on July 3, 2019, the Company received a second written notice from Nasdaq indicating that the Company is not in compliance with the requirement for continued listing on the Nasdaq Global Select Market to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Notice”).

  • GlobeNewswire

    Novelion Therapeutics Responds to Whitefort Capital Petition

    Novelion Therapeutics Inc. (NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases (“Novelion”), announced that on June 20, 2019, Whitefort Capital Master Fund, LP (“Whitefort”) filed a petition (the “Whitefort Action”) against Novelion Therapeutics Inc. (“Novelion”), as respondent, in the Supreme Court of British Columbia seeking a declaration that Novelion has breached section 301 of the Business Corporations Act of British Columbia (“Section 301 of the BCA”). The petition also includes an order pursuant to Section 301 of the BCA requiring Novelion to hold a special meeting of its shareholders to vote on whether Novelion should “dispose of” the intercompany loan between Novelion (as lender) and Aegerion Pharmaceuticals, Inc. (“Aegerion”) (as debtor) (the “Intercompany Loan”) pursuant to the terms of a Restructuring Support Agreement entered into by, inter alia, Novelion and Aegerion on May 20, 2019 in connection with Aegerion’s Chapter 11 plan of reorganization (the “Plan of Reorganization”) in the United States Bankruptcy Court, Southern District of New York (the “Bankruptcy Court”) Case No. 19-11632 (the “Aegerion Bankruptcy Case”).

  • Benzinga

    The 5 Most Expensive Drugs In US: What You Should Know

    The upward trajectory of prescription drug prices in the U.S. has drawn the ire of lawmakers. Prices of drugs are staggeringly high in the U.S. when compared to other developed countries such as Japan and in Europe. House lawmakers are discussing a plan that could work to curb high drug prices.

  • Can We See Significant Institutional Ownership On The Novelion Therapeutics Inc. (NASDAQ:NVLN) Share Register?
    Simply Wall St.

    Can We See Significant Institutional Ownership On The Novelion Therapeutics Inc. (NASDAQ:NVLN) Share Register?

    The big shareholder groups in Novelion Therapeutics Inc. (NASDAQ:NVLN) have power over the company. Generally...

  • Reuters

    UK's Amryt Pharma unites lomitapide franchise with Aegerion deal

    Britain's Amryt Pharma has agreed to buy Aegerion Pharmaceuticals, a subsidiary of Novelion Therapeutics, in a deal that reunites the franchise for lomitapide, a treatment for patients with a rare cholesterol disorder. Amryt, which already had a licence to sell lomitapide in Europe and countries including Russia, said it would raise $60 million in equity funding for the deal, which will create a group with combined proforma 2018 revenue of $136.5 million.

  • GlobeNewswire

    Novelion Therapeutics Announces Subsidiary Aegerion Pharmaceuticals to Recapitalize Through Court Supervised Process In Which Amryt Pharma Plc Will Acquire 100% of Reorganized Stock of Aegerion

    Novelion Therapeutics Inc. (NVLN) (Novelion), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that its wholly-owned subsidiary Aegerion Pharmaceuticals, Inc. (Aegerion) has entered into a plan funding agreement (PFA) and a restructuring support agreement (RSA) that will result in Aegerion selling 100% of its reorganized stock to, and becoming a wholly-owned subsidiary of, Dublin-based Amryt Pharma Plc (Amryt). The agreements, which will result in a recapitalization of Aegerion (the Recapitalization), are the result of the previously announced capital structure and strategic review undertaken independently by the Boards of Directors of Novelion and Aegerion, and a broad marketing process.

  • Associated Press

    Novelion Therapeutics: 1Q Earnings Snapshot

    The Vancouver, British Columbia-based company said it had a loss of $1.67 per share. Earnings, adjusted for non-recurring costs and stock option expense, were 10 cents per share. The retinal disease treatment ...

  • GlobeNewswire

    Novelion Therapeutics Reports First Quarter 2019 Financial Results

    Novelion Therapeutics Inc. (NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases (“Novelion” or the “Company”), today reported financial results for the first quarter ended March 31, 2019. Growth in JUXTAPID revenue in the first quarter of 2019 compared to the same period in 2018 was due to an increase in revenues in the U.S., primarily resulting from a price increase, and a greater number of patients on therapy in Japan.

  • GlobeNewswire

    Novelion Therapeutics Observes World Lipodystrophy Day

    Novelion Therapeutics Inc. (NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, in association with its subsidiary Aegerion Pharmaceuticals, today announced its observance of World Lipodystrophy Day. World Lipodystrophy Day is an international campaign designed to raise awareness about the impact of living with lipodystrophy. Interim Chief Executive Officer Ben Harshbarger said, "We stand with the patient community in honor of World Lipodystrophy Day with a mission of increasing awareness and diagnosis of this serious rare disease.

  • GuruFocus.com

    Novelion Therapeutics Inc (NVLN) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Novelion Therapeutics Inc is a biopharmaceutical company. Novelion Therapeutics Inc had annual average EBITDA growth of 2.50% over the past five years. Warning! GuruFocus has detected 2 Warning Signs with NVLN.

  • Associated Press

    Novelion Therapeutics: 4Q Earnings Snapshot

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of $1.03. Earnings, adjusted for non-recurring costs and stock option expense, were 15 cents per share. The retinal ...

  • GlobeNewswire

    Novelion Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

    Company achieves FY 2018 total net revenues of $130.4 million FY 2018 operating expenses reduced by $27.2 million, or 18.4% VANCOUVER, British Columbia, and CAMBRIDGE, Mass.,.

  • GlobeNewswire

    Novelion Therapeutics Observes Rare Disease Day

    VANCOUVER, British Columbia and CAMBRIDGE, Mass., Feb. 28, 2019 -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards.

  • ACCESSWIRE

    Biotech Stocks Set to Pop

    HENDERSON, NV / ACCESSWIRE / February 7, 2019 / Biotech stocks are what growth investors thrive on. The rewards can be staggering - prices on biotechnology shares can literally double overnight - but the ...

  • GlobeNewswire

    Novelion Therapeutics Subsidiary Enters Into Licensing Agreement for JUXTAPID® in Japan

    Novelion Therapeutics Inc. (NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases (“Novelion”), announced that its subsidiary, Aegerion Pharmaceuticals, Inc. (“Aegerion”), has entered into an exclusive licensing agreement with Recordati Rare Diseases Inc. (“Recordati”) for the commercialization of JUXTAPID® (lomitapide) in Japan. The agreement includes exclusive rights in Japan for Recordati to commercialize JUXTAPID for the current approved indication, homozygous familial hypercholesterolemia (HoFH), and Aegerion grants Recordati an exclusive right of first negotiation for product commercialization in Japan of any potential new indications that may be developed by Aegerion.

  • 5 Top Rising P/E Stocks to Enjoy Solid Gains
    Zacks

    5 Top Rising P/E Stocks to Enjoy Solid Gains

    Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.